istock-513551088-handshake
solidcolours / iStockphoto.com
22 October 2018Americas

AbbVie enters Humira licensing deal with Fresenius Kabi

AbbVie has announced that it has entered into a licensing deal with Germany-based pharmaceutical company Fresenius Kabi.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
29 September 2017   AbbVie has settled its patent dispute over Amgen’s proposed biosimilar for Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.
Americas
18 July 2018   US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.

More on this story

Americas
29 September 2017   AbbVie has settled its patent dispute over Amgen’s proposed biosimilar for Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.
Americas
18 July 2018   US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.

More on this story

Americas
29 September 2017   AbbVie has settled its patent dispute over Amgen’s proposed biosimilar for Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.
Americas
18 July 2018   US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.